Senior Correspondent, London
Ben's Feed
Oct 2, 2014
Oct 1, 2014
Oct 1, 2014
Oct 1, 2014
Oct 1, 2014
Sep 30, 2014
Sep 30, 2014

New cancer therapy comes of age, cost a “toxic” side effect

MADRID (Reuters) – A raft of new cancer drugs promise better, longer-lasting treatments with fewer adverse side effects — but their high cost is a growing concern.

Drugs that help the body’s own immune cells fight tumors are expected to be used in multi-drug cocktails, pushing the price of therapies costing more than $100,000 a year even higher.

Sep 30, 2014
Sep 29, 2014

Roche, GSK melanoma pill combinations look similar in showdown

MADRID, Sept 29 (Reuters) – Rival two-pill combinations for
melanoma from Roche and GlaxoSmithKline had
similarly good results in separate clinical trials, leaving
doctors with little to choose between the two skin cancer
courses.

The latest findings will fuel a wider debate about the
optimal treatment of melanoma as a new generation of
immune-stimulating injections offers an alternative way to fight
the deadliest form of skin cancer.

Sep 29, 2014

Hundreds of firms join global hunt for copycat biotech drugs

By Ben Hirschler

(Reuters) – Hundreds of companies around the world are chasing an emerging market for cheaper copies of costly biotech drugs, with more than 700 so-called biosimilars now in development or already approved, according to a major study of the sector.

Biotech medicines – made from proteins and other large molecules – account for six of the 10 biggest-selling drugs in the world today, led by AbbVie’s $12 billion-a-year rheumatoid arthritis injection Humira.

    • About Ben

      "Ben Hirschler is European pharmaceuticals, biotechnology and healthcare correspondent, based in London. Previously, he was in charge of British company news and before that was posted to Johannesburg, covering the economic challenges facing post-apartheid South Africa."
    • More from Ben

    • Follow Ben